ArticleOncoTargets and therapy2016
Prognostic significance of miR-126 in various cancers: a meta-analysis.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Pooled it
- Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review).International journal of oncology · 2026Review
- MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential.Cancers · 2025Article
- Circulating miR-126-3p is a mechanistic biomarker for knee osteoarthritis.Nature communications · 2025Article
- Identification of the EBF1/ETS2/KLF2-miR-126-Gene Feed-Forward Loop in Breast Carcinogenesis and Stemness.International journal of molecular sciences · 2025Article
- Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.International journal of molecular sciences · 2024Article
- Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.Cancer gene therapy · 2022Review
- Diagnostic implication of a circulating serum-based three-microRNA signature in hepatocellular carcinoma.Frontiers in genetics · 2022Article
- High expression of microRNA-126 relates to favorable prognosis for colon cancer patients.Scientific reports · 2021Article
- Review
- Crosstalk Between microRNAs and the Pathological Features of Secondary Lymphedema.Frontiers in cell and developmental biology · 2021Review
- Downregulation of microRNA-126 is inversely correlated with insulin receptor substrate-1 protein expression in colorectal cancer and is associated with advanced stages of disease.Oncology letters · 2020Article
- The prognostic value of COL3A1/FBN1/COL5A2/SPARC-mir-29a-3p-H19 associated ceRNA network in Gastric Cancer through bioinformatic exploration.Journal of Cancer · 2020Article
- Micro RNA Transcriptome Profile in Canine Oral Melanoma.International journal of molecular sciences · 2019Article
- MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.Seminars in cancer biology · 2019Review
- Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer.Journal of clinical medicine · 2019Article
- The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1.Hereditas · 2019Article
- MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- microRNA-126 Is a Tumor Suppressor of Granulosa Cell Tumor Mediated by Its Host Gene EGFL7.Frontiers in oncology · 2019Article
- Involvement of miR-126 in autoimmune disorders.Clinical and molecular allergy : CMA · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRecent studies have demonstrated that microRNA-126 (miR-126) might be a promising prognostic factor for cancer patients. This meta-analysis was conducted to assess the effectiveness of miR-126 as a prognostic biomarker for various cancers.
methodsThe search of studies was performed by using PubMed and Embase until January 22, 2016. Pooled hazard ratio (HR) with 95% confidence interval (CI) for patients' survival was calculated. A fixed-effect or random-effects model was applied according to heterogeneity. The trim and fill method was used to adjust pooled HR.
resultsIn all 17 articles comprising of 2,437 participants were included in this meta-analysis. The results indicated that a high level of miR-126 played a favorable role in the overall survival (HR 0.70, 95% CI: 0.62-0.79, random-effects model), with a heterogeneity measure index of I (2)=63.2% (P<0.01). Subgroup analyses showed that pooled HR was more significant in patients with digestive system cancers (HR 0.70, 95% CI: 0.59-0.83, fixed-effects model) and respiratory system cancers (HR 0.71, 95% CI: 0.59-0.85, random-effects model). Owing to publication bias, HR was adjusted to 0.59 (0.463-0.752, P<0.01) by the trim and fill method.
conclusionmiR-126 could be a promising biomarker for cancer prognosis prediction, especially in patients with digestive or respiratory system cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.